Selected article for: "additional treatment and clinical benefit"
Author: Boari, Gianluca E.M.; Chiarini, Giulia; Bonetti, Silvia; Malerba, Paolo; Bianco, Gianluca; Faustini, Cristina; Braglia-Orlandini, Federico; Turini, Daniele; Guarinoni, Vittoria; Saottini, Michele; Viola, Sara; Ferrari-Toninelli, Giulia; Pasini, Giancarlo; Mascadri, Cristina; Bonzi, Bianca; Desenzani, Paolo; Tusi, Claudia; Zanotti, Eros; Nardin, Matteo; Rizzoni, Damiano
Title: Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study
  • Cord-id: ue38al2b
  • Document date: 2020_12_4
    • ID: ue38al2b
    Snippet: The aim of the present study was to simultaneously assess several potential predictors of outcome (co-morbidity, previous and in-hospital treatment, radiologic Brixia score) in patients with COVID-19. This retrospective cohort study included 258 consecutive patients with confirmed COVID-19 admitted to a medical ward at Montichiari Hospital, Brescia, Italy from February 28th to April 30rd, 2020. Patients had SARS-CoV-2 related pneumonia with respiratory failure, and were treated with hydroxychlor
    Document: The aim of the present study was to simultaneously assess several potential predictors of outcome (co-morbidity, previous and in-hospital treatment, radiologic Brixia score) in patients with COVID-19. This retrospective cohort study included 258 consecutive patients with confirmed COVID-19 admitted to a medical ward at Montichiari Hospital, Brescia, Italy from February 28th to April 30rd, 2020. Patients had SARS-CoV-2 related pneumonia with respiratory failure, and were treated with hydroxychloroquine and lopinavir plus ritonavir. In some patients, additional treatment with tocilizumab, dexamethasone and enoxaparin was adopted. Outcomes (death or recovery) were assessed at the end of the discharge period or at the end of the follow-up (August 2020). During hospitalization, 59 patients died, while 6 died after discharge. The following variables were demonstrated to be associated with a worse prognosis: Radiologic Brixia score higher than 8, presence at baseline of hypertension, diabetes, chronic obstructive pulmonary disease, heart disease, cancer, previous treatment with ACE-inhibitors or anti-platelet drugs. Anticoagulant treatment during hospital admission with enoxaparin at a dose higher than 4000 U once daily was associated with a better prognosis. In conclusion, our study demonstrates that some co-morbidities and cardiovascular risk factors may affect prognosis. The radiologic Brixia score may be a useful tool to stratify the risk of death at baseline. Anticoagulant treatment with enoxaparin might be associated to a clinical benefit in terms of survival in patients with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • ace inhibitor and admission age: 1, 2
    • ace inhibitor and low molecular: 1
    • acute ards respiratory distress syndrome and admission age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and long follow: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and low flow nasal cannula: 1
    • acute ards respiratory distress syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low molecular enoxaparin weight heparin: 1
    • acute ards respiratory distress syndrome and low molecular weight heparin enoxaparin: 1
    • acute ards respiratory distress syndrome include and admission age: 1
    • acute respiratory distress syndrome and admission age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and long follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory distress syndrome and low flow nasal cannula: 1
    • acute respiratory distress syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and low molecular enoxaparin weight heparin: 1
    • acute respiratory distress syndrome and low molecular weight heparin enoxaparin: 1
    • admission age and long follow: 1
    • admission age and low molecular: 1, 2, 3, 4, 5
    • long follow and low molecular: 1